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1 Introduction
Increasingly, welfare economic evaluations are used in the 
context of the allocation of scarce healthcare resources. 
Many jurisdictions prescribe their use in the context of 
reimbursement, funding, and/or pricing of new health tech-
nologies, especially pharmaceuticals. The fact that the out-
comes of such evaluations can influence actual allocation 
decisions in healthcare underlines the importance of a sound 
methodology and an appropriate decision-making process. 
Fortunately, in both areas progress has been made over 
the past decades. However, there remains room for further 
improvement, for instance in finding appropriate estimates 
of monetary values of health, developing broader outcome 
measures than quality-adjusted life-years (QALYs), finding 
appropriate equity (principles to estimate) weights for health 
outcomes, and estimating health opportunity costs.
A topic that receives increasing attention in this context is 
the inclusion in economic evaluations of so-called spillover 
effects [1–5]. These include the health and wellbeing effects 
of illness, and treatment of patients on ‘significant others’, 
most importantly family members and informal caregivers 
[4]. These effects are commonly ignored in economic evalu-
ations, which typically treat patients as isolated individu-
als, ignoring potentially large wellbeing and health impacts 
their illness can have on family members and caregivers [2, 
3, 6, 7]. In this commentary, I argue that it is necessary to 
include these effects in economic evaluations for reasons of 
efficiency and equity. This is true for both economic evalu-
ations taking a societal perspective and those taking a nar-
rower healthcare perspective. Further investigation of their 
measurement, valuation, and consideration in the decision-
making process remains warranted.
2  Aim and Perspective of Economic 
Evaluations
Economic evaluations have their roots in welfare econom-
ics, of which the central objective is to provide an ethical 
framework for making meaningful statements about whether 
specific (policy) changes improve social welfare. As Boad-
way and Bruce state: ‘That is, the welfare economist wishes 
to determine the desirability of a particular policy—not in 
terms of his or her own values, but in terms of some explic-
itly stated ethical criteria’ [8]. Welfare economics in that 
sense is inherently normative and one may argue that the art 
of applied health economic evaluations would benefit from 
more debate on the underlying ethical criteria. The current 
exchange of views hopefully contributes to that debate.
One of the important choices in any welfare economic 
evaluation is which elements of value are to be included in 
the analysis. In theory, all aspects of value that are relevant 
to the decision the analysis is trying to support should be 
included. This decision context, reflecting the goal of the 
decision maker, relevant constraints and decision-making 
process, differs between jurisdictions when it comes to 
health economic evaluations [9]. Some countries prescribe 
a societal perspective to be taken in economic evaluations. 
Such a perspective is in line with both welfare economic 
theory and the goal of optimizing social welfare. Then, all 
relevant costs and benefits, regardless of where, when, or 
on whom they fall, need to be included in the analysis [10]. 
Only by doing so, a full welfare economic evaluation can 
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be performed and claims regarding the improvement of 
social welfare attempted to be made (difficult as they may 
be, given, for example, the ‘difficulty’ of specifying a full 
social welfare function).
Still, other jurisdictions take a narrower view of the 
decision-making aim, most notably maximizing or optimiz-
ing health from a given (fixed) budget [9]. Taking such a 
‘healthcare perspective’ typically implies the inclusion of 
only those costs that fall under the healthcare (or sometimes 
social) budget and only health effects as benefits. This can 
be viewed as being in line with the budget responsibility of 
the informed decision maker and their assumed goal (health 
optimization1). The perspective adopted and the assumed 
decision rule dictate the inclusion and exclusion of specific 
costs and benefits in the evaluation. Whereas direct (phy-
sician time, drug costs, etc.) and indirect (costs in gained 
life-years) medical costs are relevant in both perspectives, 
direct and indirect non-medical costs (e.g. travel costs and 
productivity costs, respectively) do not fall on the healthcare 
budget and would only be relevant when adopting a societal 
perspective.
Just to emphasize, adopting a societal perspective would, 
in principle, imply the inclusion of all influential costs and 
benefits. Taking a narrower perspective, such as the health-
care perspective, implies that aspects of real societal value 
are, by definition, left out of the analysis. Hence, decision 
makers are systematically left ignorant about the broader 
consequences of their decisions. Even if such consequences 
are seen as ‘external effects’ from the decision makers’ per-
spective, it is clear that this risks reducing overall welfare 
and also (indirectly) health. For example, early discharge 
could (societally speaking, wrongfully) be pictured as cost 
effective because the costs (and effects) of informal care 
are ignored. Bed rest could be advised, over treatment, 
for some illnesses because lost workdays are not valued 
(or even considered). Even if one would accept that many 
earthly decision makers have a narrower scope than improv-
ing broad social welfare, leaving them ignorant about the 
nature, scope, and size of these external effects, as a rule, 
seems hard, if not impossible, to defend. This holds both in 
theory and in practice, especially in the context of allocation 
decisions.
The sometimes heard argument that equity requires such 
ignorance is used inconsistently, appears to ignore the fact 
that equity considerations should also be informed, that 
inclusion of broader elements of value can also improve 
equity, and that, ideally, the decision maker should (be 
able to) weight these arguments, informedly! This will be 
addressed more elaborately below.
2.1  Spillover Effects
In terms of relevant outcomes, effects, or benefits, the tra-
ditional focus has been on the inclusion of health effects in 
patients. These are obviously important outcomes in any 
analysis. Still, the scope of included effects appears to be 
broadening in recent years in at least two ways. First, it is 
becoming clear that health effects may not be the only rel-
evant outcomes produced by the health and social care sec-
tor. For instance, in elderly care or palliative care, value can 
be created that may not be adequately reflected in QALY 
gains that only reflect health-related utility. New and broader 
outcome measures, including the ICECAP [11] and ASCOT 
[12] instruments, were developed in an attempt to fill this 
gap. Note that this broadens the evaluative scope of evalu-
ations as well as their use in broader contexts, which may 
also have consequences for the perspective taken because 
the combination of broader outcome measures with ‘only’ 
healthcare costs may render difficult to interpret (if not 
meaningless) incremental cost-effective ratios. Second, rel-
evant effects do not only occur in patients but also in others. 
Such effects are typically called spillover effects [1], which 
can have different characteristics and causes. Here, it is good 
to distinguish between family effects and informal caregiver 
effects, as well as between health and wellbeing effects [4].
Family effects occur in family members of the patient 
as a consequence of the health state of a loved one (‘car-
ing about’ a patient) [2, 3]. Examples include the influence 
of a serious illness of a child on the health and wellbeing 
of his/her parents, or the impact of mental health problems 
on the health and wellbeing of a partner. The impact of 
these effects can be large [6, 7]. Informal caregiver effects 
occur in caregivers due to performing physically or emo-
tionally demanding care tasks, often over longer periods of 
time (‘caring for’ a patient). Numerous studies describe the 
effects of caregiving on the health [13, 14] and wellbeing 
[2, 15] of informal caregivers, highlighting the substantial 
impact of these effects. Given that informal caregivers are 
often family members of the patient, both types of effects 
are likely to occur in caregivers [4], and when investigating 
health effects in family members [16, 17], who may also be 
caregivers, both effects are likely to be present [2, 3].
Spillover effects are relevant for health economic evalu-
ations adopting either a societal or healthcare perspective. 
From a healthcare perspective, the health effects in family 
members and caregivers are directly relevant for the deci-
sion rule that underlies the analysis: optimizing health from 
a fixed budget. Leaving out the health effects in significant 
others is inconsistent with this goal and risks decisions that 
1 I use the word ‘optimization’ rather than maximization to allow 
weighting of health gains, for instance to favor gains at the end of life, 
in young people or patients in poor health states. Such weights can be 
seen as reflecting differential social values of health gains. I empha-
size that analogous to difficulties in specifying a social welfare func-
tion, it may be difficult to specify a full ‘social health value function’.
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reduce health. Hence, it is unsurprising that in the 2013 
guidance of the National Institute for Health and Care Excel-
lence (NICE) it was already mentioned that “… all direct 
health effects, whether for patients or, when relevant, carers” 
[18] should be included in the analysis. At that time, the 
focus, also in the literature, was mainly on health effects in 
informal caregivers; however, these effects also occur in the 
broader family network [6, 7]. Ignoring these health effects 
risks missing the goal of health maximization or optimiza-
tion that these decision-making bodies apparently aim for.
From a societal perspective, health effects are also rel-
evant. In fact, the first US Panel on Cost-Effectiveness in 
Health and Medicine [10], recommending the adoption of a 
societal perspective, encouraged researchers to think broadly 
about the inclusion of health effects in significant others. 
Their inclusion in the analysis can be fairly straightforward 
[19], although more research into which health-related 
quality-of-life instruments are best suited to capture these 
effects remains important [20]. Broader wellbeing effects, 
affecting overall utility or welfare, not necessarily (only) 
health-related utility, are also relevant [3]. Their inclusion 
in economic evaluations, also for patients, is still less com-
mon and may be less straightforward, although is gaining 
attention [19]. Systematically ignoring elements of value 
that are relevant for and potentially influential in the decision 
cannot be justified in this context.
From a theoretical perspective, the inclusion of spillover 
effects is necessary in order to be able to make decisions in 
line with the specified goal. Practically, depending on the 
(relative) size and context of spillover effects, they may well 
make a difference for the final decision [6, 21]. Hence, for 
reasons of efficiency, following the decision rules underlying 
economic evaluations from a healthcare or societal perspec-
tive, inclusion is warranted.
2.2  Equity
Systematically ignoring spillover effects cannot therefore be 
justified on the grounds that they do not make a difference 
or are irrelevant. Can they be ignored then because they 
do make a difference and thus have distributional conse-
quences? In other words, would it be inequitable to include 
these effects in economic evaluations? Let me make two 
observations on that issue. First, inclusion of any cost or out-
come variable can have distributional consequences. Take 
hospital costs. If elderly normally need to stay in hospital 
longer than younger people, for certain treatments, inclusion 
of hospital costs in the analysis may have distributional con-
sequences. Would the right answer be to ignore these costs 
altogether then? Of course not. The decision maker needs 
to be informed about these aspects, including the distribu-
tional consequences in order to be able to make an informed 
decision in line with the specified goals, also trading off 
efficiency and equity goals where necessary. The argument 
to ignore specific cost aspects for reasons of equity seems to 
be used rather selectively.2 Fairness is not helped by igno-
rance, but by a full, adequate, and deliberative weighting of 
the issues at hand.
How about spillover effects? Their inclusion can, of 
course, have distributional consequences. The scope and 
nature of the consequences also depends on the type of 
decision normally taken. (Sometimes rather unlikely exam-
ples are used to argue against inclusion. For instance, only 
treating people from large families within one disease area 
seems an unlikely outcome of the decision-making process 
in many jurisdictions. More emphasis on treatments of those 
diseases with larger spillover effects compared with other 
diseases seems more realistic.) A crucial question here is 
whether the exclusion of spillover effects will lead to fairer 
decisions, as a rule. I would again argue this not to be the 
case. Take the health effects in informal caregivers. Ignor-
ing these, while including the benefits of this care in terms 
of QALY gains of patients, is not only inconsistent but, in 
my opinion, excluding the adverse health effects in these 
valuable carers is also inequitable. These people sacrifice 
time, and often their wellbeing and health, to help patients. 
They deserve our attention in the decision-making process. 
Otherwise decisions (such as early discharge from hospitals) 
could lead to increased adverse health effects in caregivers, 
without consideration. It is hard to maintain that this is fair.
The same holds for the health (and wellbeing) impacts of 
health problems on family members, which can differ per 
type of disease. Why would it be fairer to not consider that in 
some diseases (e.g. mental health problems) spillover effects 
on family members, representing real health and wellbeing 
losses, are more prominent than in others? While fairness 
may involve weighting of these effects in a deliberative pro-
cess, a case can certainly be made as to why fairness would 
benefit from their inclusion and consideration.
2 Recently, it was, for instance, used to argue against the inclusion 
of medical costs in gained life-years [22], apparently largely moti-
vated by the outcomes of inclusion (in one particular case). But again, 
ignoring these costs is inconsistent with the aims and methods of 
economic evaluations as it ignores real (health) opportunity costs of 
these expenditures [23]. It thus makes life-prolonging interventions 
seem more cost effective than they actually are and relatively more 
cost effective than quality-of-life-improving interventions. Is that 
(necessarily) fair, also for those people who will receive less care as a 
consequence? I would argue that ignoring them is not the appropriate 
answer to the problem, not consistent with the overall decision goals 
and methods, nor fairer as a rule! Deliberative consideration of these 
costs and their consequences is warranted.
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2.3  Displacement?
If the introduction of a new technology is believed to lead to 
displacement of existing care (or, more generally speaking, 
to health opportunity costs), this displacement will not only 
involve patient health and medical costs but also spillover 
effects and broader costs. It has been clearly illustrated how 
spillover effects can and should be included in such a context 
[7]. In short, both the gained and lost spillover effects need 
to be considered, leading to a consideration of ‘net spillover 
effects’. This is similar to the inclusion of other costs and 
effects when displacement is relevant.
One counterargument might be that we typically do not 
know what gets displaced. This is true, but, again, surely 
not unique for spillover effects. In the absence of guidance 
on disinvestments, what gets displaced is unknown and may 
also produce more patient health than what is allowed in 
the system [24]. This fact has not prevented us from making 
decisions, based on the available (limited) information on 
average opportunity costs, or from including patient health. 
So why would it justify ignoring spillover effects? One could 
argue that we know less about average spillover effects than 
about average marginal cost effectiveness of displacement. 
Well, if that is true, it is only more recently the case and 
would, moreover, be an excellent argument to include these 
effects. Inclusion will swiftly increase our knowledge about 
(average) spillover effects in different contexts. Broader 
investigations of spillover effects can complement this strat-
egy. The more we learn about spillover effects, including 
how to best measure, value, and include them [17, 19], the 
better we will be in estimating (average) displaced spillo-
ver effects and the more weight (net) spillover effects can 
receive in the decision-making process. Again, ignoring the 
spillover effects does not improve our knowledge nor does 
this improve the trust we should place on decisions. Using 
the available knowledge may be considered superior over 
assuming net spillover effects to be zero as a rule, for effi-
ciency and equity reasons. Inclusion in that sense at least 
allows us to be ‘vaguely right’ rather than being ‘precisely 
wrong’ with exclusion, and to become increasingly precisely 
right. More research into the measurement, valuation, and 
inclusion of spillover effects can facilitate this [25].
2.4  Concluding
Spillover effects are real and potentially large health and 
wellbeing effects in caregivers and family members. If our 
aim is to improve health or welfare, ignoring such effects 
in economic evaluations risks making decisions that do not 
improve health or welfare. Moreover, ignoring these effects 
does not, as a rule, result in fairer decisions. Full consid-
eration of relevant aspects is necessary for reasons of effi-
ciency and equity, as well as their trade-off. The inclusion of 
spillover effects in economic evaluations and their delibera-
tive consideration in the decision-making process should 
therefore be the norm.
3  Rebuttal to McCabe
While I welcome Chris McCabe’s commentary [26], it 
deserve a few words of caution of its own, especially 
because his suggestions may well harm rather than improve 
health, welfare, and equity. Here, I will briefly clarify some 
incorrect and inconsistent claims, ‘criss-crossing’ through 
his commentary.
3.1  No Regard for Opportunity Costs?
McCabe’s commentary suggests that broadening the scope 
of evaluations would ignore opportunity costs and displace-
ment. This is incorrect. On the contrary, in a societal per-
spective everyone affected by a decision should be consid-
ered. Taking a broader perspective is fully compatible with 
accounting for fixed budgets and displacement when relevant 
[9]. A framework for the inclusion of spillover effects in 
such a context has already been proposed [7]. Meanwhile, 
evidence on spillover effects is increasing, as this special 
issue of PharmacoEconomics testifies, making it increas-
ingly possible to have an idea about ‘net spillover effects’ 
whenever deemed relevant. Moreover, it seems obvious that 
McCabe’s suggestion of excluding spillover effects from 
economic evaluations and decision making is not an answer 
to the issue of opportunity costs and risks health lowering, 
inefficient and unfair decisions.
3.2  Uncertainty
Including spillover effects (like any other component in an 
economic evaluation) may increase uncertainty, but uncer-
tain relevant estimates are certainly better than certain irrel-
evant estimates of zero! Decision makers can (be trusted 
to) use the presented evidence prudently, also considering 
the uncertainty. Moreover, the uncertainty McCabe accepts 
regarding whether and which patient health is displaced (i.e. 
we normally do not know what gets displaced: “… deci-
sion makers assume that it is the least valuable health care 
activity that is displaced…”) [26], seemingly is unaccep-
table when it comes to caregivers’ health, the result being 
that their health gets ignored and potentially harmed. This 
also already signals arbitrary choices in his approach.
3.3  Arbitrary and Inconsistent
McCabe indeed draws arbitrary lines around what he wants 
to consider in a normative analysis. Take, for example, his 
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discussion of the inclusion of medical costs occurring dur-
ing life-years gained. Exclusion is inconsistent with the aim 
of health maximization he himself adopts, as it ignores real 
health opportunity costs [12]. Important distributive issues 
should of course be addressed, but ignoring real costs and 
effects risks both inefficiency and inequity.
His most crucial inconsistency is related to the statement 
regarding the purpose, as McCabe sees it, of economic 
evaluations: “The focus is on the health produced by the 
technologies, not any characteristic of the individuals who 
receive or lose health. … The key point is that decision mak-
ers are indifferent to who receives and loses health; it is 
maximizing the health produced that matters” [26]. If these 
two statements are true, then why the distinction between 
health produced (and lost) in patients versus health produced 
(and lost) in others like caregivers? These health effects are 
equally real and important under this rule and our effort 
should be on collecting the relevant evidence to make the 
best decision possible given the agreed aims (which may 
include equity considerations).
The inclusion of spillover effects is therefore fully con-
sistent with these broad aims. Ignoring (health) effects is 
not! McCabe writes that the “appropriate scope for costs and 
benefits should rely on the scope of costs and benefits identi-
fied as relevant by the decision maker for whom the analysis 
is undertaken”. NICE, perhaps most prominent in function-
ing under the assumption of a fixed budget, was, already 
in 2013, suggesting to include “… all direct health effects, 
whether for patients or, when relevant, carers” [18].
Moreover, while I fully acknowledge the ultimate respon-
sibility of decision makers in setting the scope and process 
for their decisions, I do think they should (and often want 
to) be informed by research on how to optimally do so. Take 
McCabe’s example of presenting ministers deciding on addi-
tional taxation for funding new healthcare interventions with 
a full account of costs and benefits. To subsequently fail to 
do the same when spending the money raised on the basis 
of this full account, by taking a narrower scope by a subse-
quent decision maker, clearly risks inconsistent and welfare-
lowering decisions. Understanding this may help to improve 
decision-making processes, which we cannot dictate (fortu-
nately) but can and should inform.
3.4  Procedural Justice
McCabe emphasizes the need for (procedural) justice, and 
I agree. He argues (my phrasing) that because we do not 
know what gets displaced, we should not include spillover 
effects since the (caregivers of the) people whose care is dis-
placed do not have a voice in the process. I note two things 
in response. First, since we do not know what gets displaced, 
patients harmed by displaced or forgone activities have no 
direct voice in the procedure either. They are represented in 
the estimates of opportunity costs. The same can be done 
for spillover effects [7]. Differences in certainty about the 
estimates can be reflected in decision-making weights and 
procedures. Second, judging whether something leads to 
better or worse procedures and decisions depends on the 
comparator. McCabe’s alternative is to ignore real spillover 
effects in decision making altogether. Suggesting this gives 
more voice to family members and caregivers or, as a rule, 
leads to better decisions, seems heroic. Rather, McCabe 
effectively places zero weight on changes in health in others 
in the decision-making framework by excluding them (both 
for new and displaced care!). I fail to see how this would 
be more procedurally fair or consistent with his own aims.
3.5  Concluding
McCabe’s words of caution are welcomed, and indeed any 
consideration of spillover effects should be done carefully, 
fairly, and prudently. Nothing in his argumentation provides 
a convincing argument to exclude these effects from eco-
nomic evaluations. In fact, exclusion is even inconsistent 
with the purpose he himself describes for economic evalua-
tion. Caution is therefore especially required to avoid ignor-
ing spillover effects. So, let’s agree to proceed with caution 
by (fairly, prudently, and explicitly) including (net) spillover 
effects in all future health economic evaluations!
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